Telik Inc. announced the appointment of six new members of the board of directors to help guide the company and its management in developing an expanded product development pipeline post-merger. J. David Hansen has served as MabVax's President, Chief Executive Officer, and Member of its Board of Directors since co-founding MabVax in 2006. Mr. Hansen is an experienced biopharmaceutical executive with more than 30 years of industry experience.

From 1998 to 2006, Mr. Hansen was a corporate officer of Avanir Pharmaceuticals, where he held the titles of Vice President of Commercial Development, Senior Vice President of Corporate Development, and President and Chief Operations Officer of the Avanir Subsidiary Xenerex Biosciences. Prior to 1999 Mr. Hansen served in multiple roles at Dura Pharmaceuticals including National Sales Director, Director of Marketing, and Director of Business Development, and at Merck & Co. (Schering-Plough), Key Pharmaceuticals, and Bristol Myers Squibb.

Philip O. Livingston, M.D. is a co-founder and has been a member of MabVax's Board of Directors since 2008. Dr. Livingston has served as MabVax's Chief Science Officer since 2012. He received his MD degree from Harvard Medical School and was Professor of Medicine in the Joan and Sanford Weill Medical College at Cornell University and Attending Physician and Member of Memorial Sloan-Kettering Cancer Center, or MSKCC, where he treated melanoma patients and ran the Cancer Vaccinology Laboratory research lab for over 30 years until his retirement from MSKCC in 2011.

Jeffrey V. Ravetch, M.D., Ph.D. has been a member of the MabVax Board of Directors since early 2014. Dr. Ravetch has served as the Theresa and Eugene Lang Professor at the Rockefeller University and Head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology since 1997. Kenneth M. Cohen has been a member of the MabVax Board of Directors since mid-2014.

Mr. Cohen has been a member of the Board of Directors of Adamis Pharmaceuticals Corporation from 2011 to present. Paul V. Maier has been a member of the MabVax Board of Directors since mid-2014. Mr. Maier has been a member of the Board of Directors of Apricus Biosciences Inc. from 2012 to present.

Jim J. Antonopoulos is a Principal in Canaccord Genuity's Investment Banking Group. Mr. Antonopoulos works primarily in the Life Sciences sector, representing pharmaceutical and biotechnology companies. Over the past six years, he has focused on sourcing and supporting the execution of public and private financing engagements as well as advising companies with respect to mergers and acquisitions.

Michael M. Wick, M.D., Ph.D. has served as the Company's Chairman of the Board of Directors from 2000 to July 2014. Dr. Wick served as the Company's Chief Executive Officer from 1999 to July 2014 and as its President from 1998 to July 2014. Dr. Wick served as the Company's Chief Operating Officer from 1997 until 1998, and as Executive Vice President, Research and Development, from 1997 until 1998.